ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

China's Sinopharm to extend its reach into Southeast Asia

State-backed company to launch $150m fund to look for opportunities

Sinopharm Capital, the private equity arm of China's Sinopharm Group, is on the hunt for acquisitions across Southeast Asia.   © Reuters

SINGAPORE -- Sinopharm Capital will launch a $150 million investment fund to tap into the growing Southeast Asian healthcare market.

The private equity arm of state-owned pharmaceutical giant China National Pharmaceutical Group, Sinopharm Capital will partner with Singapore's Novena Global Lifecare and Chinese private equity firm Cedarlake Capital in the hunt for acquisitions mostly in areas such as ophthalmology and renal care -- as well as new drugs and biomedical projects.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more